MILLER, DAVID,米勒 大卫,米勒 大衛,MACLEOD, ANGUS,麦克罗德 安格斯,麥克羅德 安格斯,DEL RIO GANCEDO, SUSANA,戴里欧甘塞多 苏莎娜,戴里歐甘塞多 蘇莎娜,STRATFORD, SAMUEL ALEXANDER,史特拉福德 山缪 Ａ,史特拉福德 山繆 Ａ
申请号：
TW108114167
公开号：
TW201943704A
申请日:
2019.04.23
申请国别(地区):
TW
年份:
2019
代理人:
摘要：
The present invention relates to a sodium salt ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.本發明係關於N-((1,2,3,5,6,7-六氫-s-二環戊二烯并苯-4-基)胺甲醯基)-1-異丙基-1H-吡唑-3-磺醯胺之鈉鹽及其水合物、溶劑合物及多晶型。本發明進一步係關於包含此化合物之醫藥組合物及此化合物在治療及預防醫學病症及疾病(最尤其藉由NLRP3抑制)中之用途。
